Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic

Area of Science:

• Biotechnology
• Molecular Oncology
• Drug Development

Background:

• Oligonucleotide therapeutics have advanced significantly since the 1990s, with approved drugs in other fields.
• Despite pre-clinical data, clinical translation of oligonucleotide-based cancer therapies remains limited.
• Challenges include effective drug delivery, target gene selection, and mitigating off-target effects.

Purpose of the Study:

• To review advances in oligonucleotide chemistry for therapeutic applications.
• To examine ongoing clinical trials of oligonucleotide therapeutics in oncology.
• To identify specific hurdles and potential solutions for oligonucleotide-based cancer treatment.

Main Methods:

• Literature review of nucleic acid chemistry advancements.
• Analysis of ongoing clinical trials in cancer oligonucleotide therapy.
• Exploration of nanotechnology applications in oligonucleotide delivery.

Main Results:

• Nucleic acid chemistry has enabled oligonucleotide technologies as a therapeutic alternative.
• Several clinical trials are investigating oligonucleotide-based cancer treatments.
• Nanotechnology presents a promising avenue for improving oligonucleotide delivery and efficacy in cancer.

Conclusions:

• Oligonucleotide therapeutics hold potential for cancer treatment but require overcoming significant challenges.
• Effective vectorization, precise gene targeting, and minimizing toxicity are crucial for clinical success.
• Nanotechnology integration is key to advancing oligonucleotide-based cancer therapies.